Severe asthma is a challenging condition. Available therapeutic options for severe asthma include tiotropium, omalizumab, interleukin-5 targeted therapies, macrolide antibiotics, and bronchial thermoplasty.
Your search for severe asthma returned 693 results
In phase 2a trial, time to first asthma worsening shorter with risankizumab compared with placebo
The BLA submission is supported by data from the PATHFINDER clinical program.
The FDA has approved Nucala (mepolizumab; GlaxoSmithKline) for injection as add-on maintenance treatment of patients with severe asthma aged ≥12 years.
Treatment with masitinib, a selective tyrosine kinase inhibitor, significantly reduces the rate of severe asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids, according to data from a phase 3 study.
Tezepelumab is an investigational first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin.
GlaxoSmithKline announced the launch of Nucala (mepolizumab) for the treatment of patients aged ≥12 years with severe asthma with an eosinophilic phenotype.
The Food and Drug Administration (FDA) has approved Cinqair (reslizumab; Teva) injection in combination with other asthma drugs for the maintenance treatment of severe asthma in patients aged ≥18 years.
AstraZeneca announced top-line results from two pivotal Phase 3 studies for benralizumab as adjunct to standard-of-care therapy for the treatment of severe asthma with an eosinophilic phenotype.
The designation was based on data from the Phase 2b PATHWAY trial that evaluated 3 doses of tezepelumab as add-on therapy in patients with a history of asthma exacerbations and uncontrolled asthma receiving inhaled corticosteroids/long-acting β-agonist with or without oral corticosteroids and additional asthma controllers vs placebo.